Prescription drug · ANDA
Tazarotene NDC 68308-745
Tazarotene 1 mg/g · Cream · Topical · Mayne Pharma
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68308-745-30 | 6830807453068308074530 | 1 TUBE in 1 CARTON (68308-745-30) / 30 g in 1 TUBEMarketed from Nov 10, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tazarotene
- Generic name (nonproprietary)
- tazarotene
- Active ingredients
- Tazarotene — 1 mg/g
- Dosage form
- Cream
- Route
- Topical
- Labeler
- Mayne PharmaNDC labeler code 68308
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 208662
- Marketing start
- Listing expires
- Other FDA classes
- Retinoids (Chemical structure)
- Identifiers
- Product ID 68308-745_fa8e7930-3ff4-44d5-8978-0bcabcd6e26fSPL ID fa8e7930-3ff4-44d5-8978-0bcabcd6e26fSPL set ID 0296f0e9-f940-45d9-987e-1ee26a7ca961UNII 81BDR9Y8PSUPC 0368308745307
- Pharmacologic class
- Retinoid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468308074530followed by a unit qualifier and the quantityPackage 68308-0745-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Tazarotene cream 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) 1.1 Plaque Psoriasis Tazarotene cream, 0.1% is indicated for the topical treatment of patients with plaque psoriasis. 1.2 Acne Vulgaris Tazarotene cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.
Excerpt only. Read the full label for complete information.
About NDC 68308-745
- What is NDC 68308-745?
- 68308-745 is the product NDC for Tazarotene, Tazarotene 1 mg/g cream, listed with the FDA by Mayne Pharma. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tazarotene.
- What is the active ingredient?
- Tazarotene.
- Who is the labeler?
- Mayne Pharma, NDC labeler code 68308. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tazarotene?
- 14 other product NDCs are listed under this name. See all Tazarotene NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Tazarotene products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Cosette Pharmaceuticals, Inc. | 0713-0765 | 00713-0765-3100713-0765-60 |
| Tazarotene | Tazarotene .5 mg/g | GelCutaneous | Solaris Pharma Corporation | 73473-309 | 73473-0309-1073473-0309-30 |
| Tazarotene | Tazarotene 1 mg/g | GelCutaneous | Solaris Pharma Corporation | 73473-310 | 73473-0310-1073473-0310-30 |
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Padagis Israel Pharmaceuticals Ltd | 45802-706 | 45802-0706-9445802-0706-96 |
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Bryant Ranch Prepack | 72162-2420 | 72162-2420-0372162-2420-06 |
| Tazarotene | Tazarotene .5 mg/g | GelTopical | Padagis Israel Pharmaceuticals Ltd | 45802-436 | 45802-0436-0145802-0436-94 |
| Tazarotene | Tazarotene 1 mg/g | GelTopical | Padagis Israel Pharmaceuticals Ltd | 45802-442 | 45802-0442-0145802-0442-94 |
| Tazarotene | Tazarotene 1 mg/g | GelTopical | Bryant Ranch Prepack | 72162-2202 | 72162-2202-03 |
| Tazarotene | Tazarotene 1 mg/g | GelTopical | Cosette Pharmaceuticals, Inc. | 0713-0804 | 00713-0804-3100713-0804-99 |
| Tazarotene | Tazarotene .5 mg/g | GelTopical | Cosette Pharmaceuticals, Inc. | 0713-0805 | 00713-0805-3100713-0805-99 |
Other NDCs under ANDA 208662
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tazarotene | Tazarotene 1 mg/g | CreamTopical | Cosette Pharmaceuticals, Inc. | 0713-0670 |
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Cosette Pharmaceuticals, Inc. | 0713-0765 |